National Organization for Rare Disorders Announces 2026 Rare Impact Award Honorees to Recognize Breakthroughs in Medicine and Advocacy

The National Organization for Rare Disorders (NORD®) has officially announced the recipients of its annual NORD Rare Impact Awards®, honoring a distinguished group of biopharma industry leaders, medical scientists, and patient advocates. These individuals and organizations are being recognized for their extraordinary contributions toward improving the lives of the more than 30 million Americans who are currently living with a rare disease.

The 2026 class of honorees spans a broad spectrum of the rare disease ecosystem. They include innovative biopharmaceutical companies whose novel treatments have radically altered patient outcomes, community leaders who are tirelessly raising awareness at the grassroots level, trailblazing scientists pushing the boundaries of rare disease research, and passionate public health advocates who are successfully spearheading legislative and policy changes across the United States.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

Industry Innovators in Rare Disease

Among this year’s most anticipated recognitions are five biopharmaceutical companies and one nonprofit organization—working closely alongside impacted rare disease patient communities—that are being celebrated for recent U.S. Food and Drug Administration (FDA) approvals of first-of-their-kind therapies.

The stakes in this field remain remarkably high. With approximately 95% of the more than 10,000 known rare diseases still lacking a single approved treatment, the acceleration of scientific progress is a matter of critical public health importance.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

"With approximately 95% of more than 10,000 known rare diseases still lacking an approved treatment, advancing scientific progress is critical," said Pamela K. Gavin, NORD Chief Executive Officer. "NORD is proud to honor these companies and nonprofit organizations for pioneering new therapies and advancing research that can change what is possible for individuals and families affected by these rare diseases. Their progress in addressing the unique challenges of these conditions is also contributing knowledge, approaches, and breakthroughs that help move science and the entire rare disease field forward."

The 2026 Industry Innovator honorees represent major milestones across multiple complex clinical areas. Mighty Therapeutics is being recognized for FORZINITY™, the first-ever therapy approved for Barth syndrome. Barth syndrome is an extremely rare, progressive, and life-limiting genetic condition that affects cellular mitochondria and has been shown to severely impair muscle strength and quality of life. Barth syndrome advocates, notably NORD member the Barth Syndrome Foundation, pushed for the development of this treatment for over a decade, ultimately helping secure its accelerated approval. The introduction of FORZINITY brings renewed hope not only to Barth families but also to the broader community facing rare mitochondrial diseases, who have lauded the approval as a monumental step forward for advancing clinical research and regulatory pathways.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

Another key industry honoree is UCB for KYGEVVI®, recognized as the first and only FDA-approved treatment for adults and children suffering from thymidine kinase 2 deficiency (TK2d) whose symptoms began at or before 12 years of age. Clinical data has demonstrated that KYGEVVI reduces the risk of death by over 90%, with 75% of patients regaining at least one previously lost motor skill, and many successfully reducing or eliminating their reliance on ventilatory support. This milestone was celebrated by NORD members including the United Mitochondrial Disease Foundation, MitoAction, and the Muscular Dystrophy Association, all of which spent years investing heavily in foundational mitochondrial disease research.

Gene therapy has also reached historic milestones this year. Fondazione Telethon is being honored for Waskyra™, a breakthrough gene therapy developed through decades of dedicated research at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy. Wiskott-Aldrich syndrome (WAS) is a genetically inherited primary immunodeficiency (PI) and represents the first PI condition to receive an FDA-approved gene therapy. Furthermore, Waskyra marks the first time in history that a nonprofit organization has successfully developed and brought to market an FDA-approved gene therapy. The Immune Deficiency Foundation, a prominent NORD member, celebrated this landmark achievement.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

Omeros has been recognized for YARTEMLEA®, the first and only FDA-approved treatment for adults and children aged two years and older with hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA). This condition is a severe and frequently fatal complication of stem cell transplantation, stemming from endothelial cell injury that causes dangerous blood clots in small blood vessels and subsequent damage to vital organs. Bone marrow transplant advocacy groups and specialized medical institutions have praised the targeted and potentially life-saving nature of this therapy.

In the realm of rare oncology, Jazz Pharmaceuticals is being honored for MODEYSO™, the first and only FDA-approved treatment for one of the most aggressive pediatric and young adult brain tumors: recurrent H3K27M-mutant diffuse midline glioma (DMG). Every year, approximately 2,000 American families receive this devastating diagnosis. The patient community spent more than a decade funding and participating in foundational research that made the breakthrough possible. By securing accelerated approval, Jazz Pharmaceuticals has offered patients and families the possibility of a new future.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

Verastem Oncology is also being recognized for the AVMAPKI® FAKZYNJA® CO-PACK, which is the first treatment specifically approved for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have previously undergone systemic therapy. This rare cancer carries a severe unmet medical need, with historical response rates to traditional chemotherapy and hormone therapy remaining under 14%. With clinical response rates reaching 44%, the combination treatment and routine molecular testing for KRAS are anticipated to establish a new standard of care for LGSOC.

Individuals and Organizations Honored

Beyond industry advancements, NORD is honoring the individuals and grassroots organizations whose dedication transforms the daily reality for the one in ten Americans living with a rare disorder.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

The Foundation for Prader-Willi Research (FPWR) is the recipient of the prestigious Abbey S. Meyers Leadership Award. As a dedicated NORD member, FPWR leads patient-centered research into Prader-Willi syndrome (PWS) utilizing its Global PWS Registry, which was built on NORD’s IAMRARE® patient registry platform. Insights gathered from this registry were instrumental in securing last year’s FDA approval of VYKAT™ XR, the first approved treatment to address excessive hunger—one of the hallmark challenges of PWS. This historic milestone marked the first known instance of IAMRARE data directly contributing to an FDA drug approval.

Dr. Stephanie E. Haridopolos, a board-certified family medicine physician and prominent public health official, is the recipient of the Policy Changemaker Award. Her career bridges clinical practice and high-level government service, having previously served as Chief of Staff of the Office of the Surgeon General and currently as its Director of National Health Communications. Dr. Haridopolos has been a vital advocate for rare disease patients, helping facilitate the U.S. Department of Health and Human Services’ decision to add Duchenne muscular dystrophy and metachromatic leukodystrophy to the Recommended Newborn Screening Panel (RUSP). Since May 2026, she has also performed the interim duties of the Surgeon General.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

Several individuals have been honored with Community Champion Awards for their localized and regional impact. Dr. Julieta Bonvin Sallago of Connecticut, an international medical graduate living with a rare disease, is pursuing a career as a genetic counselor while working in clinical trial recruitment at Connecticut Children’s Hospital for the Glycogen Storage Disease Program—the exact family of disorders she was diagnosed with. She has leveraged her scientific and cultural expertise to support NORD’s volunteer community, helping organize Latino patient and family listening sessions, translating NORD Rare Disease Reports into Spanish, and recruiting Spanish-speaking participants for the NORD® Living Rare Study.

Lily Emmanuel of Colorado has been recognized for her passionate advocacy and volunteer leadership in expanding rare disease awareness across the western United States. Through her work with NORD Running for Rare® in Colorado, Emmanuel has created inclusive opportunities for individuals impacted by rare disorders to engage in advocacy and fundraising through wellness initiatives, forging strong relationships with hospitals, local running groups, and patient communities.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

Dr. Maureen Helgren of Connecticut has transformed rare disease education by integrating it directly into the core curriculum at the Frank H. Netter, MD School of Medicine at Quinnipiac University. She established a dedicated rare disease course, founded the annual Netter Rare Disease Symposium, and regularly brings patients into the classroom. Serving as the faculty advisor for Quinnipiac University’s NORD Students for Rare® chapter, Dr. Helgren helps reduce diagnostic delays by preparing future physicians to recognize rare conditions and advocate passionately for affected communities.

Medical and Scientific Trailblazer Awards have been presented to prominent clinical researchers whose work has fundamentally shifted the landscape of rare disease medicine. Dr. Susan A. Berry of Minnesota, operating through the University of Minnesota Medical School NORD Rare Disease Center of Excellence, has defined a model of care for inborn errors of metabolism in close collaboration with patient advocates like the National PKU Alliance. Nationally, her work extends to advising on newborn screening policies and advocating for medical foods and formulas while serving on NORD’s Board of Directors.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

Dr. Stephen Kingsmore, Founding President and CEO of the Rady Children’s Institute for Genomic Medicine—a NORD Rare Disease Center of Excellence in California—has pioneered whole genome sequencing, established rapid genetic testing as a standard clinical tool, and developed the first comprehensive genomic carrier screening test. Given that approximately 80% of rare diseases are genetic in origin, Dr. Kingsmore continues to advance precision medicine through emerging digital platforms.

Mark Skinner, JD of New York has received the Lifetime Achievement Award for his extensive leadership in bleeding disorders advocacy at state, national, and international levels. Having led the World Federation of Hemophilia and the National Bleeding Disorders Foundation, Skinner has consistently ensured that patient-reported outcomes inform healthcare decision-making, contributing his expertise to NORD’s Board of Directors, the Institute for Clinical and Economic Review (ICER), and advisory panels on blood safety and rare disease research.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

Paridhi Tyagi of New Jersey has been honored with the Youth Leadership Award. After founding a genetics club at Millburn High School, Tyagi partnered with NORD Students for Rare to educate her peers. For Rare Disease Day, she organized library displays and coordinated morning announcements sharing patient stories. She also established a collaboration with Girl Scouts USA focused on genetics and rare disease education, leading workshops that taught younger participants about inclusion and foundational science. Her dedication was further underscored by her active participation as a high school student at the NORD Breakthrough Summit.

"Each of these 2026 Rare Impact Award winners demonstrates the power we each have as individuals to drive change in our communities, whether that’s as an advocate, policymaker, scientist, or physician," Gavin remarked. "They inspire us all to persevere in our shared mission to alleviate the physical, emotional, and financial strain that rare diseases place on too many individuals and families."

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

The Community Champion, Policy Changemaker, Youth Leader, Lifetime Achievement, and Abbey S. Meyers Leadership Awardees are being recognized in person at the NORD Breakthrough Summit® in Washington, D.C. Meanwhile, the Scientific and Medical Trailblazer Awardees were honored earlier this year at the NORD® Rare Disease Scientific Symposium, and CEO Pamela Gavin is personally presenting the Industry Innovation Awards to recipient companies at their U.S. headquarters.

Asep Darmawan

Penulis aktif di HypePress yang membagikan konten inspiratif, informasi terkini, dan gaya hidup untuk generasi muda.

Artikel Bermanfaat dan Menghibur Lainnya